Together, these processes lead to CTLA-4-mediated ligand removal, cytokine-driven maturation arrest, and PD-L1-dependent tolerization, explaining why reduced CD80/CD86 is a recurring feature of the HPV-independent cervical cancer microenvironment and a key barrier to effective antitumor T-cell activation. This evidence concerns the gene CD274 and cervical cancer.